Optimising Clinical Trial Data Collection for Better Decisions

Clinical trial data collection has become one of the biggest challenges in modern drug development. As protocols grow more complex and decentralised approaches expand, sponsors must balance collecting sufficient evidence for regulators with reducing unnecessary burden on patients and research sites.

New research suggests that collecting more data does not always produce better clinical evidence. Instead, success increasingly depends on optimising clinical data collection. 

Image

Why Clinical Trial Data Collection has Become Increasingly Complex

Clinical trials generate enormous volumes of information throughout development. Electronic case report forms (eCRFs), laboratory results, imaging, wearable devices, electronic patient-reported outcomes (ePROs), and real-world data have expanded both the opportunities and challenges of evidence generation.

While digital technologies have improved data availability, protocol complexity has also increased significantly over the past two decades.

More assessments, additional endpoints, and increasing administrative requirements place growing pressure on investigators, trial participants, contract research organisations (CROs), and sponsors.

Recent analysis published in Therapeutic Innovation & Regulatory Science argues that this expansion has created a common misconception: That collecting more data automatically strengthens a clinical trial.

Instead, optimising clinical trial data collection requires a fundamental shift from quantity to quality. The authors propose that every data point should have a clear scientific purpose, helping sponsors improve efficiency while maintaining robust evidence for regulatory approval.

This is because excessive data collection can introduce new problems, including:

• increased workload for research sites
• higher operational costs
• greater potential for missing or inconsistent data
• longer database cleaning and analysis timelines
• increased participant burden and reduced retention

The challenge is therefore no longer simply collecting data. It is ensuring that every measurement contributes meaningfully to answering the study’s objectives.

The Case for ‘Fit-for-Purpose’ Data Collection

A central recommendation from the paper is adopting a fit-for-purpose approach to clinical trial data collection.

Rather than treating every potential variable as equally valuable, sponsors should determine whether each data element directly supports:

• the primary study objective
• participant safety
• regulatory requirements
• secondary scientific objectives
• future evidence generation

Data that do not contribute meaningfully to these objectives should be carefully reconsidered.

This philosophy aligns with broader regulatory trends encouraging risk-based quality management, streamlined trial design, and proportionate oversight.

Regulators increasingly recognise that unnecessary complexity can compromise both trial efficiency and data quality.

Optimised data collection begins during protocol development, not after study initiation.

Cross-functional collaboration between clinical scientists, biostatisticians, data managers, medical monitors, operations teams, and regulatory specialists is essential to identify truly critical data.

Read The Future for Decentralised Clinical Trials

The Future for Decentralised Clinical Trials

Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.

Collecting Better Data, Not Simply More Data

The paper introduces several practical principles that can improve clinical trial data quality while reducing unnecessary burden.

Prioritise critical data

Sponsors should distinguish between critical-to-quality (CtQ) data and information that has limited impact on study outcomes.

Critical data generally include:

• primary efficacy endpoints
• participant safety information
• informed consent documentation
• eligibility criteria
• investigational product accountability
• protocol compliance

Focusing quality management efforts on these areas allows monitoring resources to be directed where they deliver the greatest value.

Eliminate redundant data

Many clinical trials continue to collect historical variables simply because they appeared in previous protocols.

You can routinely challenge whether legacy assessments remain scientifically justified.

Removing unnecessary procedures can reduce investigator workload, shorten participant visits, and improve overall trial efficiency.

Improve protocol design

Optimised data collection begins with better protocol design.

Clear study objectives make it easier to identify which assessments are genuinely necessary and which provide limited additional value.

This also supports more efficient database design, statistical analysis planning, and regulatory submission preparation.

Digital Technologies Create New Opportunities

Modern clinical trials increasingly rely on digital technologies to capture richer, more continuous data than traditional site visits alone.

These include:

• electronic clinical outcome assessments (eCOAs)
• wearable sensors
• remote patient monitoring
• electronic health records
• decentralised clinical trial platforms
• digital biomarkers

While these technologies can improve participant convenience and generate valuable longitudinal insights, the paper cautions against collecting continuous data without a clearly defined analytical purpose.

Simply because technology enables continuous measurement does not mean every available data stream improves decision-making.

Sponsors should evaluate whether digital endpoints are clinically meaningful, validated, and aligned with study objectives before incorporating them into protocol design.

A Framework for Optimising Clinical Trial Data

Sponsors should adopt a structured framework for evaluating every proposed data element before trial initiation.

Questions include:

• Does this data directly support the primary endpoint?
• Is it required for participant safety?
• Will regulators expect this evidence?
• Can existing data sources provide the same information?
• Does the benefit justify the operational burden?

Image

Applying these questions systematically can reduce unnecessary complexity while preserving scientific integrity.

Importantly, optimisation should not be viewed as reducing scientific rigour. Rather, it enables sponsors to focus resources on collecting higher-quality evidence that better supports regulatory and clinical decision-making.

Better Data Will Mean Better Trials

As clinical trials become increasingly global, decentralised, and data intensive, efficient evidence generation is becoming a competitive advantage.

Sponsors that continue expanding protocols without carefully evaluating each assessment risk increasing costs while reducing operational efficiency.

Conversely, organisations that adopt structured, risk-based approaches to clinical trial data collection may achieve several benefits:

• faster database lock and analysis
• improved site satisfaction
• reduced participant burden
• higher-quality datasets
• more efficient monitoring
• improved inspection readiness

These improvements become increasingly important as adaptive trial designs, decentralised clinical trials, precision medicine, and AI-assisted analytics continue reshaping clinical development.

Rather than asking how much data can be collected, leading organisations are increasingly asking which data truly matter.

Better Clinical Evidence Begins with Better Questions

There is an important principle for modern clinical development: High-quality evidence depends more on thoughtful study design than on the volume of information collected.

Optimising clinical trial data collection requires sponsors to align every assessment with scientific objectives, participant safety, and regulatory expectations. By eliminating unnecessary complexity and focusing on critical data, organisations can improve trial efficiency without compromising evidence quality.

This reflects a broader shift towards smarter clinical development that delivers reliable evidence while reducing burden across the clinical trial ecosystem.

At Pharmatica, we examine the strategies, technologies, and regulatory developments shaping the future of clinical development. Our analysis helps pharmaceutical leaders understand how operational excellence, smarter trial design, and evidence-based innovation can improve both development efficiency and patient outcomes.

Pharmatica: Insight. Connection. Impact.

Image